Peer Exchange

Impact of Cardiovascular Evidence on Diabetes
October 02, 2017 – 
John B. Buse, MD, PhD, discusses the potential impact that the recent cardiovascular outcomes trials will have on clinical decision making and future research in diabetes.
Understanding Cardiovascular Benefit With the LEADER Trial
October 02, 2017 – 
John B. Buse, MD, PhD, offers his perspective on the LEADER trial with liraglutide and the potential reasons for the cardiovascular effects in patients with type 2 diabetes.
The Importance of Real-World Data in Type 2 Diabetes
September 27, 2017 – 
Mark Warren, MD, discusses the role for real-world studies in type 2 diabetes and outlines important factors to consider when evaluating the relevance of the findings.
Understanding the DUAL VII Findings in Type 2 Diabetes
September 27, 2017 – 
Mark Warren, MD, provides context to the efficacy and safety findings from the DUAL VII trial with liraglutide plus insulin degludec in patients with type 2 diabetes.
GLP-1 Receptor Agonists: Initial Cardiovascular Evidence
September 25, 2017 – 
John B. Buse, MD, PhD, reviews the findings from the ELIXA trial with lixisenatide in patients with type 2 diabetes.
Cardiovascular Benefit With SGLT2 Inhibition
September 25, 2017 – 
John B. Buse, MD, PhD, discusses the potential reasons for the cardiovascular risk reduction benefits associated with SGLT2 inhibition in patients with type 2 diabetes mellitus.
Impact of Cardiovascular Data in Type 2 Diabetes
September 12, 2017 – 
Mark Warren, MD, offers insight regarding the recent cardiovascular outcomes trials in type 2 diabetes.
Access to Therapeutic Combinations in Type 2 Diabetes
September 12, 2017 – 
Mark Warren, MD, explains some of the benefits associated with the GLP-1 receptor agonist/insulin combinations and the importance of formulary access to these newer agents.
Hypoglycemia: An Unrecognized Complication in Diabetes
September 05, 2017 – 
Mark Warren, MD, discusses the lack of accurate data on the rates of hypoglycemia in the outpatient setting among patients with diabetes.
Clinical Evidence of Insulin Degludec in Type 2 Diabetes
September 05, 2017 – 
Mark Warren, MD, reviews the clinical trial evidence with insulin degludec in type 2 diabetes, highlighting the recent DEVOTE trial and what it adds to the SWITCH study findings.
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome to the new and improved AJMC.com, the premier managed markets network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!